Janet L Kwiatkowski

faculty photo
Professor of Pediatrics (Hematology) at the Children's Hospital of Philadelphia
Consulting Hematologist, Pennsylvania Hospital
Consulting Hematologist, Hospital of the University of Pennsylvania
Director, Thalassemia Program, Children's Hospital of Philadelphia
Clinical Director, Sickle Cell and Red Cell Disorders Curative Therapy Center (CuRED)
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
Division of Hematology
3501 Civic Center Blvd
Hub Room #13547
Philadelphia, PA 19104
Office: 215-590-5286
Fax: 215-590-3992
Education:
B.S. (Zoology)
Duke University, summa cum laude, 1988.
M.D.
Columbia University, College of Physicians & Surgeons, 1992.
MSCE (Clinical Epidemiology and Biostatistics)
University of Pennsylvania, 2003.
Post-Graduate Training
Intern in Pediatrics, Johns Hopkins Hospital, 1992-1993.
Resident in Pediatrics, Johns Hopkins Hospital, 1993-1995.
Fellow in Pediatric Hematology/Oncology, The Children's Hospital of Philadelphia, 1995-1998.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Optimization of iron chelation, monitoring transfusional iron overload, stroke prevention in sickle cell disease, headaches in sickle cell disease, complications of thalassemia, transfusion therapy, gene therapy for hemoglobinopathies

Description of Itmat Expertise

The research interests of Dr. Kwiatkowski include stroke and stroke prevention in sickle cell disease, transfusional iron overload and chelation therapy, diagnosis and treatment of clinical complications of thalassemia, and gene therapy for hemoglobinopathies.

Selected Publications

Hamdy M, El-Beshlawy A, Verissimo MPA, Kanter J, Inusa B, Williams S, Lee D, Temin NT, Fradette C, Tricta F, Ebeid FSE, Kwiatkowski JL* Elalfy MS* (*Authors contributed equally to the work): Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. Pediatric Blood & Cancer 71(1): e30711, Jan 2024 Notes: Online ahead of print.

Khandros, E Kwiatkowski, J: Thalassemia Syndromes: Quantitative Disorders of Globin Chain Synthesis. Wintrobe's Clinical Hematology, 15th edition. George M. Rodgers Bertil Glader Daniel A. Arber Robert T. Means Frederic R. Appelbaum Angela Dispenzieri Todd A. Fehniger Laura Michaelis John P. Leonard (eds.). Wolters Kluvwer Health, Inc, Philadelphia, PA, 2023

Kwiatkowski JL: Gene addition for beta thalassemia. Annals of the New York Academy of Sciences 1530(1): 105-109, Dec 2023.

Dulmovits BM, Wild KT, Filbotte J, Lampert MP, Kwiatkowski J, Thom CS. : Neonatal thrombocytopenia as a presenting finding in de novo pyruvate kinase deficiency. Neonatology 120(5): 661-665, July 2023 Notes: In press.

Kwiatkowski JL: Clinical challenges with iron chelation in beta thalassemia. Hematol Oncol Clin North Am 37(2): 379-391, April 2023.

Elalfy MS, Hamdy M, El Beshlawy A, Ebeid FSE, Badr M, Kanter J, Inusa BP, Adly A, Williams S, Kilinc Y, Lee D, Fradette C, Rozova A, Toiber Temin N, Tricta F, Kwiatkowski JL: Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years. Blood Adv 7(4): 611-619, Feb 2023.

Locatelli F, Lang P, Corbacioglu S, Li A, de la Fuente J, Wall D, Meisel R, Shah AJ, Liem R, Mapara M, Carpenter B, Kwiatkowski J, Cappellini MD, Kattamis A, Sheth S, Grupp S, Kohli P, Shi D, Ross L, Bobruff Y, Simard C, Zhang L, Morrow PK, Hobbs B, Frangoul H, the CLIMB THAL-111 Team: Transfusion independence after exagamglogene autotemcel in patients with transfusion-dependent beta thalassemia. EHA, 2023 2023.

Kwiatkowski, JL and Smith-Whitley, K: Hemoglobinopathies. Nelson Textbook of Pediatrics. Kliegman, RM and St. Geme, JW (eds.). Elsevier, 22nd edition, 2023 Notes: In press.

Mark C. Walters, Janet L. Kwiatkowski, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Shamshad Ali, Ilya Shestopalov, Maeva Fincker, Richard A. Colvin, Dustin Whitney, Franco Locatelli, Alexis A. Thompson: Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials. Blood 140(Supplement 1): 5355-5357, Nov 2022.

Franco Locatelli, Mark C. Walters, Janet L. Kwiatkowski, Marina Cavazzana, Suradej Hongeng, John B. Porter, Adrian J. Thrasher, Andreas E. Kulozik, Isabelle Thuret, John E.J. Rasko, Evangelia Yannaki, Martin G. Sauer, Shamshad Ali, Himal Thakar, Katiana Gruppioni, Alexis A. Thompson: Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia. Blood 140(Supplement 1): 8200-8202, Nov 2022.

back to top
Last updated: 01/03/2024
The Trustees of the University of Pennsylvania